Anavex Life Sciences Corp (AVXL)

[georgejjl]

APOE (rs429358/rs7412) N = 32 (N* = 21)
genotype e2/e3 e3/e3 e3/e4 e4/e4
n (n*) 1 (1) 14 (10) 13 (7) 4 (3)
N: Number of total patients.
N*: Number of patients with WES data.
n: Number of patients in each genotype group.
n*: Number of patients in each genotype having WES data.

Anavex Phase 2a trial

This analysis showed that the higher blarcamesine (ANAVEX2-73) mean concentration arm had improved therapeutic responses of 78% and 88% in adjusted MMSE and adjusted ADCS-ADL, respectively, relative to the low/medium arm at 148 weeks (P-values < .0008 and <.0001, respectively). In addition to time, APOE e4 status (P < .0001), and blarcamesine (ANAVEX2-73) mean concentration were significant predictors (Figure 2a and 2b and Supplementary Tables 4b, 4c ). Additional significant variables in this model were SIGMAR1 p.Gln2Pro, COMT p.Leu146fs, and APOE4 e4 status interactions with time.

https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/trc2.12013

See slide 16 at the following link

In addiBon to ConcentraBon,
the significant covariates
identified in MMRM-LME
model are:
SIGMAR1 (p<0.0080),
COMT (p<0.0014) and
APOE e4 status (p<0.0001)

https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/trc2.12013

Good luck and GOD bless,